卵巢上皮性癌中GST-π、TopoⅡβ、MDR1的表达及其与化疗疗效的关系

Expressions of GST-π,TopoⅡβ and MDR1 in ovarian epithelial carcinoma tissues and their chemotherapeutic responses

目的观察卵巢上皮性癌化疗耐药基因谷胱甘肽S-转移酶-(GST-)、拓扑异构酶(TopoⅡ)和多药耐药基因1(MDR1)mRNA水平表达及其与化疗疗效的关系。方法采用逆转录-聚合酶链反应(RT-PCR)检测60例卵巢上皮性癌和60例正常卵巢组织GST-、TopoⅡ和MDR1 mRNA的表达。结果正常组织中GST-及MDR1mRNA为阴性表达,TopoⅡmRNA为阳性表达。卵巢癌中GST-mRNA阳性表达为51.67%,各病理类型间差异无统计学意义(P>0.05),不同肿瘤分化程度阳性表达率差异无统计学意义(P>0.05),晚期患者阳性表达率高于早期(P<0.05)。TopoⅡmRNA阳性表达率为55%,各病理类型间差异无统计学意义(P>0.05),不同肿瘤分化程度阳性表达率差异无统计学意义(P>0.05),早期患者阳性表达率高于晚期(P<0.01)。MDR1 mRNA阳性表达率为35%,各病理类型间差异无统计学意义(P>0.05),高中分化组间差异无统计学意义(P>0.05),中低分化间差异有统计学意义(P<0.05),高低分化组间差异有显著统计学意义(P<0.01),临床分期间阳性表达率差异无统计学意义(P>0.05)。讨论检测GST-、TopoⅡ和MDR1对卵巢癌化疗药物的选择具有指导意义,在一定程度上能预测化疗疗效。

Objective To investigate expressions of Glutathione-s-transferase-π（GST-π）,topoisomeraseⅡβ（Topo Ⅱβ）and multi-drug resistance gene 1（MDR1）in ovarian epithelial carcinoma tissues and their significances.Methods Reverse transcriptase polymerase chain reaction was used to detect expressions of GST-π mRNA,TopoⅡβ mRNA and MDR1mRNA in 60 cases with ovarian epithelial carcinoma and 60 cases with normal ovarian.The relations between the expression and the clinical-pathological characteristics as well as chemotherapeutic responses were discussed.Results GST-π mRNA and MDR1 mRNA were negative in normal ovarian tissue,while TopoⅡβ mRNA was postive.The positive rate of GST-π mRNA in ovarian epithelial carainoma tissues was 51.67%： there were no statistical significances among different pathological types and differential degrees（P0.05）;positive rate of late period was higher than that of early period（P0.05）.The positive rate of TopoⅡβ in ovarian epithelial carcinoma was 55%： there were no statistical significances among different pathological types and differential degrees（P0.05）;positive rate of early period was higher that of late period（P0.05）.The positive expression rate of MDR1 in ovarian epithelial carcinoma tissues was 35%,and a significant relationship was shown between its expression and pathologic differentiation degrees（P0.05）,but there was no statistical differences among clinical stages.ConclusionsFor ovarian epithelial carcinoma patients,chemotherpeutic responses can be prediceted by detecting the expressions of GST-π,TopoⅡβ and MDR1.